n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, November 6th, 2017

The QualityStocks
Daily Stock List

graphic
graphic

Ethos Gold Corp. (ETHOF)

Stockhouse, Streetwise Reports, MarketWatch, InvestorsHub, YCharts, 4-Traders, The Street, and TradingView reported on Ethos Gold Corp. (ETHOF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Ethos Gold Corp. focuses on the acquisition and exploration of mineral properties globally. At present, the Company holds one property in the White Gold District in the Canadian Yukon territory. Ethos Gold has 100 percent ownership in the WC property. The Company mainly explores for gold, antimony, arsenic, lead, as well as silver deposits. Ethos Gold’s shares trade on the OTC Markets Group’s OTCQB.

Incorporated in 2007, Ethos Gold has its head office in Vancouver, British Columbia. The Company previously went by the name Ethos Capital Corp. It changed its corporate name to Ethos Gold Corp. in April of 2012.

Mr. Gary Freeman is the Chairman, President & Chief Executive Officer of Ethos Gold. Mr. Freeman is an entrepreneur and financier. He has held several executive positions. In addition, he has been instrumental in financing, marketing and shareholder relations' capacities with a number of junior exploration companies.

Ethos Gold’s WC property consists of 44 contiguous quartz claims totaling roughly 815 ha. The WC property is a target for intrusion-related 'Pogo-style' mineralization or fault controlled epithermal systems such as the close by Coffee Deposit.

The Company contracted Ground Truth Exploration, Inc. in 2012 to conduct a small 301 soil geochemical sampling program for the WC property. This was completed in July of 2012. The program intention was to identify areas of interest based on anomalous gold in soil values and to ascertain the mineral potential of the property.

Samples were collected along 10 sample lines. Individual samples were collected with 50 meters between stations along traverse lines.

A total of 14 sample sites returned values in excess of 10 ppb Au with a maximum value of 171 ppb Au. The sample with the second highest gold concentration (119 ppb Au) has coincident anomalous antimony (19 ppm Sb), arsenic (117 ppm As), lead (200 ppm Pb), and silver (13 ppm Ag).

This anomalous multi-element chemistry is alike to that identified by Ethos Gold at the Betty property, attributed to bonanza vein mineralization derived from and related to Western Copper's Casino Au-Cu-Mo porphyry.

Ethos Gold Corp. (ETHOF), closed Monday's trading session at $0.1303, even for the day. The average volume for the last 60 days is 5,966 and the stock's 52-week low/high is $0.10/$0.2319.

TurnKey Capital, Inc. (TKCI)

MarketWatch, InvestorsHub, and TradingView reported on TurnKey Capital, Inc. (TKCI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, TurnKey Capital, Inc. aligns with and builds value in private, public, and development-stage companies. It works to identify opportunities in high-growth sectors, with an initial concentration on the developing cannabis industry. The Company formerly went by the name Train Travel Holdings, Inc. It changed its corporate name to TurnKey Capital, Inc. in February 2016. TurnKey Capital is headquartered in Fort Lauderdale, Florida.

A business advisory enterprise, Turnkey Capital provides a wide array of services. These include equity and debt financing for growth, strategic operational and management resources, and financial advice, modeling, and long term corporate and shareholder support.

The Company engages companies that have missing elements within the financials and operations of their company. These missing elements restrict companies’ ability to expand.

Turnkey Capital establishes value for company shareholders through securing debt and equity positions in select companies. As a result, the Company builds a group of undervalued businesses, which it will work to increase in value. Therefore, this enables TurnKey Capital shareholders to benefit from enhanced value alongside client companies.

In January 2017, Turnkey Capital announced that it executed a Letter of Intent (LOI) with Brand Strategy Group International. This is to engage in brand license and management within an extensive range of categories.

TurnKey Capital has identified Brand Strategy Group, Inc. (BSGI) as its first potential licensing partner. Brand Strategy Group owns all intellectual property (IP), licenses, trademarks, and trade names associated with the men's fashion brand, Phillip Acker™.

This past July, Turnkey Capital announced that it signed a strategic alliance agreement with Seminole Indian Company. This agreement is to provide business formation, development, as well as financial infrastructure services to unique opportunities afforded by tribal sovereignty.

Leading the Seminole Indian Company team is former Seminole Tribal Chairman, Mr. James E. Billie. Mr. Billie is credited with kindling the $33 billion Indian gambling industry.

Important requirements of TurnKey Capital are capital structure and shareholder relations. In essence, the Company approaches venture-capital from a financial viewpoint.

TurnKey Capital, Inc. (TKCI), closed Monday's trading session at $0.10, up 0.10%, on 500 volume with 1 trade. The average volume for the last 60 days is 12,184 and the stock's 52-week low/high is $0.02/$0.2675.

North America Frac Sand, Inc. (NAFS)

PennyPickAlerts, PennyStockProfessor, TheNextBigTrade, Stock Commander, Fortune Stock Alerts, SMS Penny Picks, eliteotc, Wall Street Beauties, WINNINGOTC, BestDamnPennyStocks, DSR News, and Penny Stock Hub reported on North America Frac Sand, Inc. (NAFS), and we also report on the Company, here at the QualityStocks Daily Newsletter.

North America Frac Sand, Inc. is a development stage enterprise listed on the OTC Markets’ OTCQB. The Company owns renewable land leases with the right to extract frac sand from significant mineral deposits located in the Province of Saskatchewan. It has 29,000 acres of leases and lease options 30 kilometers east of Saskatoon. North America Frac Sand is headquartered in Saskatoon, Saskatchewan.

The Company has established relationships with all the major well service companies. These include a number of large oil & gas companies. In addition, North America Frac Sand has government and municipality support.

Frac Sand is a proppant utilized in the oil and gas industry as part of the hydraulic fracturing process - a method to enhance flow to the wellhead. North America Frac Sand’s strategy is to realize a significant presence in the frac sand industry through developing a long term, high quality, and secure supply of frac sand for the oil & gas industry in Western Canada and the Northwestern U.S.

Frac sand must have definite characteristics. These include reaching certain levels of crush resistance, sphericity, as well as roundness. Therefore, frac sand is a relatively rare commodity.

North America Frac Sand’s short-term plan is to prove out the balance of its major resource. Its long-term plan is to commence shipments of frac sand as soon as possible.

Moreover, its strategy is to develop and maximize the mineral deposit under its land and optioned leases, and to develop a long-term relationship with well service and oil & gas companies that focus on quality service and product. North America Frac Sand’s strategy also involves providing a year-round supply of frac sand to customers.

In 2015, North America Frac Sand announced the acquisition of North America Frac Sand (CA) Ltd. and its acres of leases. In 2016, North America Frac Sand announced the completion of the due diligence obligatory preceding the decision to close on the acquisition of North America Frac Sand (CA) Ltd. (NAFS-CA).

On May 25, 2017, North America Frac Sand received its initial "Technical Report" addressing its Eagle Creek Property in Saskatchewan. The Technical Report was prepared in accordance with the requirements of National Instrument 43-101 Standards of Disclosure for Mineral Projects (NI 43-101) by Norwest Corporation of Calgary, Alberta. It encompasses exploration to date on a portion of the Company’s leased areas (approximately 12,100 hectares [29,900 acres]). Following Norwest's development of the mineral resource model, an in-place sand resource of normally used frac sand size fractions in the tested area was calculated.

North America Frac Sand, Inc. (NAFS), closed Monday's trading session at $0.011, down 16.67%, on 85,742 volume with 5 trades. The average volume for the last 60 days is 93,616 and the stock's 52-week low/high is $0.0081/$0.0949.

LED Medical Diagnostics, Inc. (LEDIF)

SmallCapVoice, StreetInsider, and equities Canada reported previously on LED Medical Diagnostics, Inc. (LEDIF), and we report on the Company today, here at the QualityStocks Daily Newsletter.

LED Medical Diagnostics, Inc., by way of its wholly-owned subsidiaries, LED Dental, Inc., LED Dental Ltd., and Apteryx, Inc., provides dentists and oral health specialists with advanced diagnostic imaging products and software. This is in addition to the award-winning VELscope® Vx tissue fluorescence visualization technology. LED Medical Diagnostics’ shares trade on the OTC Markets Group’s OTCQB. Founded in 2003, the Company has its corporate office in Vancouver, British Columbia.

In February 207, LED Medical Diagnostics announced the closing of the acquisition of Apteryx, Inc. (established in 1995). Apteryx formed to create and develop software applications and systems that are top products in their respective industry segments.

Apteryx’s products include XrayVision and XVlite, an imaging suite of applications that digitize x-rays and other images for dental practitioners. Also, its products include XrayVision DCV DICOM software for the institutional dental market; XVWeb, a cloud-based PACS and DICOM server; and other Windows-based applications and utilities.

LED Medical Diagnostics’ proprietary technologies include the VELscope Vx Enhanced Oral Assessment and TUXEDO Intraoral Sensors. This is in addition to Apteryx's XrayVision, XVWeb, and XrayVision DCV imaging software solutions.

The Company’s VELscope® Vx is for use in the early visualization, discovery, and surgical treatment of oral mucosal abnormalities. The VELscope® Vx, the latest model release of VELscope technology, employs natural tissue fluorescence to discover abnormalities in the oral mucosa.

Additionally, LED Medical Diagnostics has its RAYSCAN 3D Imaging products - RAYSCAN Alpha Plus and RAYSCAN Alpha 3D. It also has its 3Shape TRIOS Intraoral Scanners; TUXEDO Intraoral Sensor; LED IC100 Intraoral Camera; LED IC200 Intraoral Camera; Apteryx Imaging Software; and Xelis 3D Imaging Software.

LED Medical Diagnostics earlier announced the issuance of a US patent to its acquired subsidiary Apteryx entitled "System and Method for Dentition Specific Image Enhancement" (patent no. 9579073). This patent discloses systems and methods for automatically generating x-ray image acquisition and processing settings that apply specifically to the type of patient and dental structure undergoing examination.

In September, LED Medical Diagnostics announced that American Dental Partners (ADPI) chose the Company's wholly-owned subsidiary, Apteryx, as its provider for cloud dental imaging software technologies. American Dental Partners will transition their whole network to Apteryx's XVWeb cloud imaging technology within the next 12 months.

ADPI enables affiliated practitioners to concentrate on exceptional patient care. This is while receiving the business services required to build vital, profitable practices, which serve their local communities.

Last month, LED Medical Diagnostics announced that Dental Care Alliance (DCA) chose the Company's wholly-owned subsidiaries, LED Dental and Apteryx as its preferred providers for dental imaging devices and software technologies. Dental Care Alliance’s dedication is to the improvement of patient care by way of inventive practice-support solutions. DCA is one of the U.S.’s largest and oldest dental support organizations. It has 265 affiliated practices across all dental specialties in 13 states.

LED Medical Diagnostics, Inc. (LEDIF), closed Monday's trading session at $0.056, down 3.28%, on 125,658 volume with 20 trades. The average volume for the last 60 days is 39,339 and the stock's 52-week low/high is $0.032/$0.074.

URZ Energy Corp. (URZZF)

OTC Markets, Streetwise Reports, Stockhouse, Morningstar, Investors Hangout, and TradingView reported on URZ Energy Corp. (URZZF), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

URZ Energy Corp. is a uranium exploration and development company listed on the OTC Markets Group’s OTCQB. It mainly engages in the evaluation, acquisition, and development of prospective ISR uranium properties in the U.S. URZ Energy owns the Gas Hills, Juniper Ridge, and Shirley Basin properties in Wyoming. In addition, the Company owns properties in Utah and Colorado. URZ Energy has its head office in Vancouver, British Columbia.

On October 12, 2017, URZ Energy announced that its common shares commenced trading on the OTCQB Venture Market in the U.S. under the symbol "URZZF”. Mr. Glenn Catchpole, URZ Energy’s Chief Executive Officer, said at that time, “Our application and subsequent trading on the OTCQB Venture Market is the Company’s first step of its long-term strategic plan to increase its American and International visibility.”

Mr. Catchpole is a licensed engineer. He has 39 years of uranium experience. This includes extensive work with Cameco Corporation on its Inkai Project in Kazakhstan.

URZ Energy’s Gas Hills Project is in the historic Gas Hills Uranium District. The Project is situated 45 miles east of Riverton, Wyoming. The Gas Hills Project comprises about 11,000 acres of unpatented lode mining claims, State of Wyoming, and private mineral leases. The Project is positioned within a brownfield site that has experienced broad development and mine and mill site production.

The Company’s advanced stage Juniper Project is situated in the southwest portion of Wyoming, about 10 miles west of the town of Baggs. This Project comprises roughly 3,300 acres of unpatented lode mining claims and State of Wyoming mineral leases. The Project is positioned within a brownfield site that has experienced wide-ranging exploration, development, as well as mine production.

The URZ Shirley Basin project region and district is home to other prominent companies. These are Cameco, Pathfinder, and UR-Energy.

This past July, URZ Energy announced that it started a technical and historic review of its wholly-owned Shirley Basin uranium project in Carbon County, Wyoming. This project comprises 3,290 acres. This includes 126 mining claims and 2 state mineral leases. The project claims sit proximal to Ur-Energy, Inc.’s and Cameco Corporation’s respective Shirley Basin projects, both of which contain earlier published NI 43-101 (National Instrument 43-101) uranium resources.

Moreover, in July, URZ Energy announced that it established a corporate office in Casper, Wyoming. This office will serve as the headquarters for a determined growth strategy. This Casper office will lead the Company’s assessment of acquisition opportunities in the region. This is addition to planning the technical activities on URZ Energy’s wholly-owned Gas Hills and Juniper Ridge resource projects in Wyoming.

URZ Energy Corp. (URZZF), closed Monday's trading session at $0.37, even for the day, on 38,591 volume with 6 trades. The average volume for the last 60 days is 18,779 and the stock's 52-week low/high is $0.31/$0.565.

iGambit, Inc. (IGMB)

Tip.us, SeriousTraders, StocksToBuyNow, and the TheMicrocapNews reported earlier on iGambit, Inc. (IGMB), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Established in 1996, iGambit, Inc. is pursuing specific medical strategies and goals. These goals have included, among others, the acquisition of medical technology companies with strong growth potential easily recognized in the public arena. iGambit focuses on the medical technology markets. The Company’s primary mission is the expansion of its newly acquired medical technology business HealthDatix, Inc. OTCQB-listed, iGambit is based in Smithtown, New York.

In August 2016, iGambit announced that it entered into an LOI (Letter of Intent) with EncounterCare Solutions, Inc. (ECSL). Under the terms of the LOI, iGambit would purchase certain assets of CyberCare Health Network, Inc. and would assume certain specifically identified liabilities. The CyberCare™ Solutions Food and Drug Administration (FDA) approved, secure online web application permits clinicians, other professionals, and family members to manage or monitor health and wellness plans.

In addition, in August 2016, iGambit and HubCentrix signed an LOI.
Under the terms of the LOI, iGambit would acquire substantially all the assets of HubCentrix (St. Petersburg, Florida-based). HubCentrix serves clients across the United States.

HubCentrix has a special expertise in streamlining the process of capturing and managing information in the document-intensive medical field. It is at the vanguard of web-based collaboration and digital asset management.

On February 14, 2017, iGambit acquired HubCentrix by way of a Stock Exchange Agreement. HubCentrix will initially operate as a wholly-owned subsidiary of iGambit and the name was changed to HealthDatix, Inc.

iGambit acquired the CyberCare Health Network Division from EncounterCare Solutions, Inc. (ECSL) in April of this year.  With this agreement, iGambit purchased certain assets of EncounterCare. Payment was made in the form of iGambit stock. CyberCare will operate as a division of the recently acquired HubCentrix Company, whose new name is HealthDatix, Inc.

HealthDatix’s goal is to identify a patient's eligibility for Medicare reimbursed doctor visits to access and assist in the well-being and cultivation of a healthy lifestyle. Furthermore, HealthDatix can provide an FDA approved, Medicare covered platform, for constant management of chronic care patients.

Last month, iGambit announced that its wholly-owned subsidiary, HealthDatix, entered into a contract with Endeavor Plus. HealthDatix will provide an online Health Risk Assessment (HRA) tool to make possible the implementation of HealthDatix's Individual Health Questions (IHQ). The tool will help employers who participate in the Endeavor Plus Plan with the data analytics on their employee population.

Last week, iGambit announced that HealthDatix entered into a contract with Axcel Electronics Thailand Co Ltd. HealthDatix and Axcel signed a mutually exclusive supply agreement. This agreement is for the design and manufacture of Wearable Health Wrist Bands for use in conjunction with HealthDatix's CareDatix solution and particularly its Electronic House Call FDA approved Tele-Health remote monitoring system.

iGambit, Inc. (IGMB), closed Monday's trading session at $0.1342, even for the day. The average volume for the last 60 days is 63,854 and the stock's 52-week low/high is $0.01/$0.40.

AdvanSource Biomaterials Corp. (ASNB)

TopPennyStockMovers, Zacks, Money Morning, S.A. Advisory, and Nebula Stocks reported previously on AdvanSource Biomaterials Corp. (ASNB), and today we report on the Company, here at the QualityStocks Daily Newsletter

Headquartered in Wilmington, Massachusetts, AdvanSource Biomaterials Corp. is an ISO certified materials technology company. Specialists in polyurethane technologies, AdvanSource provides a variety of material formats for use in long and short-term implants and disposable products. Fundamentally, the Company is a foremost developer of advanced polymer materials for an extensive range of medical devices. AdvanSource Biomaterials lists on the OTCQB.

AdvanSource serves the medical device and pharmaceutical market. A manufacturing enterprise providing medical grade thermoplastic polyurethane materials, the Company’s expertise lies in the synthesis and formulation of polymeric materials with a broad spectrum of physical and chemical properties. These materials possess innovative characteristics including biocompatibility and biodurability, and can be tailored for specific properties, including lubricity and antimicrobial formats.

AdvanSource’s materials have a history of use in short and long-term implant applications. These include stents, artificial heart valves, VADs, catheters, guidewires, as well as introducers.

Markets served include orthopedics, cardiovascular, drug delivery, endoscopy, neurology, urology, spine, interventional radiology, peripheral vascular, ENT, gastroenterology, oncology, and diabetes management. The Company’s technical services include coating capabilities to assist with prototype development.

AdvanSource’s business model takes advantage of its proprietary materials science technology and manufacturing expertise. This is to expand its product sales and royalty and license fee income. The Company’s biomaterials are used in devices designed for treating a wide array of anatomical sites and disease states. AdvanSource’s products include ChronoFlex AL; ChronoFlex AR; ChronoFlex C; ChronoPrene; ChronoSil; ChronoThane P; ChronoThane T; HydroMed; HydroThane; and PolyBlend.

The Company’s new product extensions enable it to customize its proprietary polymers for specific customer applications in a broad assortment of device categories. Furthermore, AdvanSource manufactures specialty hydrophilic polyurethanes that mainly sell to customers as part of exclusive arrangements.

Its PolyBlend is a family of very soft, aromatic polyurethane elastomeric alloys. These can be utilized as a substitute for natural rubber or latex in many applications. Its HydroMed is a series of ether-based hydrophilic urethanes with premier adhesive and cohesive properties.

Its ChronoFlex AL is a family of biodurable aliphatic polycarbonate-based thermoplastic urethanes. The design of these is to overcome surface degradation such as stress-induced microfissures.

Concerning services, in addition to customized solvent packages, the design of AdvanSource’s coating capabilities is to help with a customer’s prototype development via multi-step dip/spray coating processes for small volumes.

AdvanSource Biomaterials has a strategic alliance with Medibrane, Ltd. The Strategic Alliance provides for technology collaboration, development, and commercialization of medical coatings utilizing AdvanSource’s material technologies in collaboration with Medibrane’s coating and surface modification technologies and enhancements.

Medibrane is a top Israeli coating technology company. It designs, develops, and manufactures customized polymeric surgical implants, implantable device coatings, encapsulation coatings, and bio-absorbable implants. The intention of these is for a varied range of MIS in fields such as neurology, cardiovascular, cardiology, and urology, and also for gastroenterology, biliary, and respiratory devices.

AdvanSource Biomaterials Corp. (ASNB), closed Monday's trading session at $0.071, down 15.98%, on 3,336 volume with 2 trades. The average volume for the last 60 days is 21,358 and the stock's 52-week low/high is $0.036/$0.10.

graphic

The QualityStocks
Company Corner

graphic
graphic

Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF)

The QualityStocks Daily Newsletter would like to spotlight Petroteq Energy Inc. (FTSSF). Today, Petroteq Energy Inc. closed trading at $0.925, up 3.94%, on 62,035 volume with 75 trades. The stock’s average daily volume over the past 60 days is 17,285, and its 52-week low/high is $0.015/$1.6717.

Petroteq Energy Inc. (TSX.V:PQE) (OTCQX:PQEFF) (FRANKFURT: MW4A) today announces a co-development agreement with First Bitcoin Capital Corp. (OTC: BITCF) in which the companies will develop a new supply chain management platform based on advanced blockchain technology to be used in the global oil and gas industry.

Petroteq Energy Inc. (TSX.V: PQE) (OTCQB: PQEFF), with headquarters in Canada, seeks to create the world's largest pure-play cobalt exploration and development company. The company's current focus is on its Greater Cobalt Project located in Silver Centre, Ontario. The company is also in the midst of a three-way merger with Cobalt One Ltd. and CobalTech Mining Inc. and on completion First Cobalt will control over 10,000 hectares of prospective land and 50 historic mining operations in the Cobalt Camp in Ontario, Canada, as well as a mill and a permitted refinery facility.

The merger agreements with Cobalt One Ltd. and CobalTech Mining Inc., announced earlier this year, will result in a combined land position of more than 10,000 hectares (nearly 25,000 acres) in the Cobalt Camp containing approximately 50 past cobalt/silver producers and working mines. Initial test results from a mineralogical assessment of sample material taken from various historical mines located throughout the Cobalt Camp show both cobalt-rich and silver-rich mineralization styles. Samples taken at the former Bellellen mine, located within the Greater Cobalt Project in Ontario, show high grade cobalt assays, prompting First Cobalt to increase its drilling program at that site.

Petroteq Energy Inc. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world's current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

The company's clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, Petroteq Energy Inc. and its mining interests are primed for success.

Petroteq Energy Inc. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance. Disclaimer

Petroteq Energy Inc. Company Blog

Petroteq Energy Inc. News:

Petroteq Energy, Inc. and First Bitcoin Capital Corp. Announce Blockchain-based Initiative to Optimize Oil & Gas Supply Chain Management

Petroteq Energy Inc. Secures Interest-Free Loan From Founder to Increase Facility and Accelerate Production Capacity

Petroteq Energy Inc. Announces Issuance of Shares

First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF)

The QualityStocks Daily Newsletter would like to spotlight First Cobalt Corp. (FTSSF). Today, First Cobalt Corp. closed trading at $0.5514, up 0.18%, on 77,265 volume with 45 trades. The stock’s average daily volume over the past 60 days is 52,578, and its 52-week low/high is $0.3148/$0.67.

First Cobalt Corp. (TSX VENTURE:FCC) (OTCQB:FTSSF) (the "Company") is pleased to announce its management team will be presenting at two upcoming conferences, the Precious Metals Summit, Zurich and the Eight Capital Battery Conference, Toronto.
Precious Metals Summit, Zurich (November 7-8, 2017)
Vice President, Exploration, Dr. Frank Santaguida to present Wednesday, November 8 at 10:00am (UTC+1), Room 2
Presentation will be webcast live here (Webcast Link), and available for replay following the conference. 
Eight Capital Battery Conference, Toronto (November 15, 2017)
President and CEO, Trent Mell to present at 11:25 am (UTC-5)
The Company will also be available for one-on-one meetings during both conferences. 

First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF), with headquarters in Canada, seeks to create the world's largest pure-play cobalt exploration and development company. The company's current focus is on its Greater Cobalt Project located in Silver Centre, Ontario. The company is also in the midst of a three-way merger with Cobalt One Ltd. and CobalTech Mining Inc. and on completion First Cobalt will control over 10,000 hectares of prospective land and 50 historic mining operations in the Cobalt Camp in Ontario, Canada, as well as a mill and a permitted refinery facility.

The merger agreements with Cobalt One Ltd. and CobalTech Mining Inc., announced earlier this year, will result in a combined land position of more than 10,000 hectares (nearly 25,000 acres) in the Cobalt Camp containing approximately 50 past cobalt/silver producers and working mines. Initial test results from a mineralogical assessment of sample material taken from various historical mines located throughout the Cobalt Camp show both cobalt-rich and silver-rich mineralization styles. Samples taken at the former Bellellen mine, located within the Greater Cobalt Project in Ontario, show high grade cobalt assays, prompting First Cobalt to increase its drilling program at that site.

First Cobalt Corp. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world's current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

The company's clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, First Cobalt Corp. and its mining interests are primed for success.

First Cobalt Corp. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance. Disclaimer

First Cobalt Corp. Company Blog

First Cobalt Corp. News:

First Cobalt to present at Precious Metals Summit and Eight Capital Battery Conference

First Cobalt Reports 0.8% Cobalt over 0.5 Metre in Early Drill Results

First Cobalt Prepares to Welcome Paul Matysek, Bob Cross, and Jason Bontempo to Board of Directors

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.36, even for the day, on 808,198 volume with 333 trades. The stock’s average daily volume over the past 60 days is 514,304, and its 52-week low/high is $0.09/$0.72.

CFN Media Group, the leading creative agency and media network dedicated to legal cannabis, announces publication of an exclusive video interview with Eric A. Adams, CEO of InMed Pharmaceuticals Inc. (CSE: IN)(CSE: IN.CN)(CNSX: IN)(OTCQB: IMLFF). In this interview, CEO Eric A. Adams talks about the company's recent breakthrough, a study in which the team was able to identify a cannabinoid drug candidate for the treatment of glaucoma; biosynthesize that cannabinoid; develop a proprietary hydrogel delivery system; and effectively apply the new drug to the eye in a positive preclinical study.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

CFN Media Exclusive CEO Interview: InMed Pharmaceuticals' Biosynthesis Platform Results in an Industry First

NetworkNewsWire Announces Publication Discussing Companies Developing Novel Methods of Extracting Medicinal-Grade Cannabinoids

Economic Impact of Biosynthesis on the Cannabis Industry

MGX Minerals Inc. (MGXMF)

The QualityStocks Daily Newsletter would like to spotlight MGX Minerals Inc. (MGXMF). Today, MGX Minerals Inc. closed trading at $0.7961, off by 0.47%, on 360,426 volume with 155 trades. The stock’s average daily volume over the past 60 days is 107,608 and its 52-week low/high is $0.11/$2.119.

MGX Minerals Inc. (CSE:XMG) (FKT:1MG) (OTCQB:MGXMF) is pleased to report that engineering partner PurLucid Treatment Solutions has been awarded a non-repayable contribution totaling up to C$8.2 million in government funding to support the commercialization of a low energy water treatment system for the oil and gas industry. Specifically, Sustainable Development Technology Canada and Emissions Reduction Alberta have agreed to fund up to $3.2 million and $5 million, respectively.

MGX Minerals Inc. (CSE: XMG) (FKT: 1MG) (OTCQB: MGXMF) is a diversified Canadian resource company developing large-scale mineral portfolios in specific commodities and jurisdictions in North America. The company controls significant interest in lithium, magnesium and silicon assets that offer streamlined development timelines and low capital expenditures. MGX Minerals and its engineering partner have developed a patent-pending, low-energy design process to extract valuable minerals from the abundant, highly mineralized brine wastewater produced each year by oil and gas companies.

This proprietary, petrolithium process rapidly concentrates lithium and other minerals from brine in less than a day. That's a stunning advancement from the conventional method of extracting minerals from brine through an evaporation process that can take up to 18 months, requires hundreds of acres of land, and averages less than a 50 percent mineral recovery rate. Using this advanced water purification technology, MGX Minerals cleans the wastewater that accompanies petroleum as it's being pulled up to the surface. The company's petrolithium process eliminates the need to inject contaminated wastewater back into the ground, which prevents drinking water contamination and possible earthquakes.

In January 2017, MGX Minerals successfully recovered concentrated lithium from heavy oil evaporator blowdown wastewater using its rapid recovery process, an accomplishment independently confirmed by the Saskatchewan Research Council. In August 2017, the company also successfully processed wastewater and lithium brine from eight North American projects at its one-cubic-meter-per-hour processing plant, proving the technology is economically viable. Research group Global Water Intelligence expects the wastewater treatment industry to grow into a $45 billion market annually by 2025, which suggests there are ample revenue-generating opportunities for MGX Minerals technology.

Lithium, the "white gold" of the new energy economy, is the key to clean energy development as global demand for hybrid and electric vehicles, high-drain portable electronic devices, and large-scale energy storage systems ramps up. Grand View Research, Inc. reports that the global lithium-ion battery market is expected to reach $93.1 billion by 2025. Current market forces show a high demand for lithium and a low supply, which further supports the necessity of MGX Mineral's cleaner, faster method of extracting high-value minerals from brine wastewater.

MGX Minerals is led by a team of industry standout performers who have worked in the mining and technology industries for decades. The leadership team is joined by an array of top-notch technical partners with unmatched experience in the oil and gas sectors, environmental services industry, marketing and product development, along with applied research and commercial development of technologies. Disclaimer

MGX Minerals Inc. Blog

MGX Minerals Inc. News:

MGX Minerals Engineering Partner PurLucid Awarded C$8.2M to Manufacture and Deploy Wastewater Treatment Systems Central to MGXs Petrolithium Recovery Process

MGX Minerals’ Joint Venture Partner Power Metals Drills 26.0 Metres of 1.94% Li2O and 323.75 ppm Ta at Case Lake Property

NetworkNewsWire Announces Publication on Public Companies Racing to Meet Swelling Global Demand for Lithium

AV1 Group, Inc. (AVOP)

The QualityStocks Daily Newsletter would like to spotlight AV1 Group, Inc. (AVOP). Today, AV1 Group, Inc. closed trading at $0.04, off by 6.32%, on 181,768 volume with 20 trades. The stock’s average daily volume over the past 60 days is 227,374 and its 52-week low/high is $0.017/$0.3499.

AV1 Group, Inc. (OTC: AVOP), a publicly traded investment and holding company, today announced that through its wholly-owned subsidiary, XFIRE Smart Systems, it has initiated a pilot program for a major city in Michigan to design and implement its SMART City transition with an estimated order of approximately $5,500,000. XFIRE Smart Systems' partner, Apollo Smart Lights, a provider of LED lighting solutions, will manufacture the lighting product for the projects.

AV1 Group, Inc. (AVOP), is a publicly traded investment and holding company established to identify, secure and monetize emerging growth companies in a number of sectors that include cannabis related technologies, grow houses and cultivation, and e-commerce businesses positioned for exponential growth. After identifying businesses displaying revolutionary concepts able to develop a substantial footprint in high-growth markets, the business model followed calls for incubating and supporting the best opportunities.

The company seeks to discover inspired entrepreneurs with innovative ideas that are poised for significant revenue generation. Management expertise can be seen in the development of embryonic-stage subsidiaries as the company brings a spectrum of backgrounds to the table with a significant resource of knowledge and experience to every venture. AV1 Group explores every opportunity to help each sector exceed its revenue goals while building close, active working relationships as it prepares each respective division to be a robust competitor within the various chosen markets.

AV1 Group companies include:

  • XFIRESmartSystems.com – Intelligent lighting solutions and wireless access for many different applications.
  • VaporHighUSA.com – Over 800 vaping products; bitcoin payments accepted.
  • DentalCannatizer.com – Revolutionary dual jet dental water jet integrates hemp oil infusing.
  • IntelligentLightingCorp.com – Comprehensive, energy-efficient lighting solutions.
  • CannaLighting.com – Wholly owned subsidiary building strategic relationships in the LED sector to provide solutions for grow houses and cultivation centers.
  • MJIQ – First, comprehensive, enterprise-grade integrated software suite being developed for the legal cannabis industry.
  • Hemptory.com – Engaging online destination for all hemp and cannabis related products and services.
  • Lawster.com – Puts consumers and small businesses in contact with legal services and service providers.
  • MJTestLabs.com – Under development website will serve cannabis dispensaries, laboratories and industry affiliates.

AV1 Group's business model delivers an advantage with internally-created projects that are poised for revenue generation and a cross-company revenue platform that enables the company to incubate and foster growth in early-stage subsidiaries under one umbrella. Disclaimer

AV1 Group, Inc. Blog

AV1 Group, Inc. News:

AV1 Group Announces Pilot for SMART transition of a Major Michigan City for $5.5 Million

AV1 Group, Inc. (AVOP) is “One to Watch”

AV1 Group Appoints New CFO and Digital Marketing Director

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $0.69, up 15.19%, on 1,185,316 volume with 486 trades. The stock’s average daily volume over the past 60 days is 128,146 and its 52-week low/high is $0.1701/$0.699.

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

NetworkNewsWire Announces Publication on the Wide-Ranging Potential of Patented Technology for Improved Bioabsorption

Lexaria Bioscience Receives Groundbreaking U.S. Patent Allowance for its DehydraTECH™ Delivery of THC, NSAIDs, Nicotine and Vitamins

NetworkNewsWire Announces Publication Highlighting Recent Developments in Drug Delivery Technologies

Tapinator, Inc. (TAPM)

The QualityStocks Daily Newsletter would like to spotlight Tapinator, Inc. (TAPM). Today, Tapinator, Inc. closed trading at $0.1698, up 6.13%, on 108,582 volume with 19 trades. The stock’s average daily volume over the past 60 days is 77,268 and its 52-week low/high is $0.0711/$0.2419.

Tapinator, Inc. (TAPM) is a developer and publisher of mobile games on the iOS, Google Play and Amazon platforms. The Company's portfolio includes over 300 mobile gaming titles generating hundreds of thousands of daily player downloads that provide predictable and attractive returns through the sale of branded advertisements and consumer app store transactions. Tapinator, based in New York and with product development teams located throughout the world, was founded in 2013 by a visionary team that has been building mobile games and applications since 2007 and has achieved multiple successful exits.

Tapinator's business strategy includes the creation of a select number of best-in-class Full-Featured Games, such as ROCKY™ and Solitaire Dash, which provide game players with more in-depth, unique content that supports long-term retention and generates higher investment returns. The Full-Featured Games model creates the potential for sustainable $100+ million franchise-type games that have product lifespans of at least five years. Tapinator uses a proprietary set of dynamic development and marketing processes factored upon gaming category, estimated player retention and projected player profitability.

Recent successful launches of two new Full-Featured titles – Big Sport Fishing 2017 and Dice Mage 2 – were recognized on the Apple iOS platform as "New Games We Love." During the game's first seven days after global release, Big Sport Fishing 2017 received well over 520,000 player downloads. Four new titles, ColorFill, Divide & Conquer, Shadowborne and Fusion Heroes, are in the pipeline for release in Q4 2017 and Q1 2018 as well. The formula for these game combines proven gameplay elements with best-in-class monetization systems, supplemented by Tapinator's strong creative team of developers, strategists and product specialists. The company's Rapid-Launch Games division also saw increasing player interest recently with the launch of Fidget Spinner Superhero and Scary Shark Evolution 3D.

Tapinator's diversified revenue sources includes 54 percent from advertising placed within its mobile games and 46 percent from consumer app store purchases. The Company limits advertising placements to between game levels and also runs rewarded video ad units that are tied directly into the game's currency. Tapinator's portfolio includes more than 300 active titles, with no single game accounting for more than 25 percent of total revenues during the first half of 2017.

As Tapinator looks toward the future, opportunities in Virtual Reality (VR) and Augmented Reality (AR) show great promise. The company has released several prototype VR games to gather data before pursuing a more significant VR product. Recent market reports suggest that the VR industry will hit $30 billion by 2020 and the AR industry will surpass that with a projected $120 billion. Tapinator also plans to pursue publishing transactions that leverage its network, platform relationships and operational excellence. Significant opportunities for expanding Tapinator's gaming IP to new platforms such as Steam and leading messaging apps are also on the horizon. The company is targeting a 30+ percent annual bookings growth target for 2017-2019. Disclaimer

Tapinator, Inc. Blog

Tapinator, Inc. News:

Tapinator Announces Publishing Partnership with Robot Cake Games

Tapinator, Inc. (TAPM) Engages NetworkNewsWire for Corporate Communications Solutions

NetworkNewsWire Releases Exclusive Audio Interview with Tapinator, Inc. (TAPM)

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

TopPennyStockMovers
(ARSC) +130.00%

2.

ProTrader
(AMCT) +96.08%

3.

Jason Bond
(DCIX) +80.11%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251